Phillips Medisize Showcases Advanced Inhaled Drug Delivery Platforms at DDL 2025 Following Vectura Acquisition
Key Insights
Phillips Medisize (search) will present its expanded inhaled drug delivery capabilities at the Drug Delivery to the Lungs conference in Edinburgh, marking nearly one year since acquiring Vectura (search).
The company's presentations highlight patient-centric inhalation platforms including the FOX Vibrating Mesh Nebulizer (search), Dry Powder Inhaler (search), and nasal formulation technologies designed for precision drug delivery.
Scientific presentations will cover breakthrough research in powder deagglomeration, lipid nanoparticle stability, and automated testing systems that reduce aerosol performance testing time fivefold.
Phillips Medisize (search), a Molex (search) company specializing in pharmaceutical drug delivery device manufacturing, will showcase its enhanced inhaled drug delivery capabilities at the Drug Delivery to the Lungs conference (DDL 2025) in Edinburgh, Scotland, December 10-12. The presentation comes as the company marks nearly one year since acquiring Vectura (search), a move that significantly expanded its inhalation technology portfolio.
Expanded Capabilities Through Strategic Acquisition
Since acquiring Vectura (search) less than a year ago, Phillips Medisize (search) has broadened its inhaled drug development capabilities across small molecules, macromolecules, biologics and combination products. The acquisition has strengthened the company's position in the competitive inhaled therapeutics market, enabling more comprehensive solutions for pharmaceutical partners.
"As we mark the one-year anniversary of our acquisition of Vectura (search), we're proud to reflect on the substantial progress we've made in delivering a broader portfolio of innovative inhalation solutions, as well as demonstrate the strength of our combined expertise," said Charlie Schumacher, vice president, Global Innovation and Development UK at Phillips Medisize (search).
Patient-Centric Inhalation Platforms
The company's DDL presentations will highlight three key patient-centric inhalation platforms designed to improve precision drug delivery and support patient adherence while scaling efficiently from clinical trials to commercial manufacturing:
The FOX Vibrating Mesh Nebulizer (search) enables consistent delivery of solutions and nanosuspensions, providing reliable dosing for liquid formulations. The Dry Powder Inhaler (search) (DPI) technology is adapted to deliver precise dosing including higher payloads in a robust and stable manner. Additionally, nasal formulation and device technologies offer alternative delivery routes for targeted therapeutic applications.
Scientific Research Presentations
Phillips Medisize (search) scientists will present five research studies addressing critical challenges in inhalation drug delivery:
Advanced DPI Technology
Baudouin Géraud will present research on "Powder deagglomeration in a chaotic flow: an introduction to the O1 high payload DPI device," describing how the deagglomeration system enables efficient handling of large payloads and delivery of high fine particle doses (<5 μm) across variable inspiratory effort.
Lipid Nanoparticle Innovations
Two presentations focus on lipid nanoparticle (LNP) technology. Mireia Puig-Sellart and colleagues will demonstrate how amorphous shell formers like trileucine (search) preserve colloidal stability in LNPs, enabling higher-dose delivery without compromising performance. Neil Forbes and his team will explore how PEGylation improves vesicle characteristics for intranasal delivery of mRNA (search) surrogate poly(A), supporting future applications in respiratory and systemic therapies.
Testing and Safety Improvements
Stephanie Bannister and colleagues will highlight a partially automated testing system that reduces aerosol performance testing time fivefold while capturing diagnostic data efficiently. Additionally, Bindu Harshini Cherukuri will present research evaluating nitrocellulose-free foil as a solution to mitigate N-nitrosamines, showing no negative impact on product stability over 12 months.
Industry Impact and Future Outlook
"Our DDL presentations reflect our ongoing research into critical challenges in inhalation drug delivery," said Geraldine Venthoye, chief scientific officer and vice president, Global Medical at Phillips Medisize (search). "By sharing data on formulation stability, delivery efficiency and product robustness, we aim to inform the next generation of inhalation therapies."
The research presentations underscore Phillips Medisize (search)'s commitment to advancing inhalation science through evidence-based innovation. The company's expanded capabilities position it to address growing demand for sophisticated inhaled therapeutics across multiple therapeutic areas, from respiratory diseases to systemic drug delivery applications.